A Surgeon General Report Once Cleared the Air About Smoking. Is It Time for One on Vaping?
NEW YORK — Sixty years ago, the U.S. surgeon general released a report that settled a longstanding public debate about the dangers of cigarettes and led to huge changes in smoking in America. Today, some public health experts say a similar report could help clear the air about vaping. [time-brightcove not-tgx=”true”] Many U.S. adults believe nicotine vaping is as harmful as — or more dangerous than — cigarette smoking. That’s wrong. The U.S. Food and Drug Administration and most scientists agree that, based on available evidence, electronic cigarettes are far less danger...
Source: TIME: Health - January 15, 2024 Category: Consumer Health News Authors: Mike Stobbe / AP Tags: Uncategorized wire Source Type: news

Pope Francis makes his first public appearances since being stricken by bronchitis
Pope Francis on Thursday made his first public appearance outdoors since being stricken by bronchitis two weeks ago, which forced him to cancel a planned trip to the COP28 climate conference in Dubai. The pope has been steadily recovering, and for the Dec. 8 holiday devoted to Mary kept a…#dubai #spanish #palestinians #israelis #stpeterssquare (Source: Reuters: Health)
Source: Reuters: Health - December 8, 2023 Category: Consumer Health News Source Type: news

European Commission approves Roche ’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA)
Evrysdi available to treat people of all ages with SMA in the European Union, including babies from birth1Approval is based on interim data from ongoing RAINBOWFISH trial showing majority ofEvrysdi-treated babies were able to stand and walk within timeframes typical of healthy babies by 12 months ’ treatment2,3Evrysdi is the only non-invasive SMA therapy and is approved in 100 countries with more than 11,000 patients treated globallyBasel, 29 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved the extension of the Evrysdi ® (risdiplam) European Union (EU) marketing ...
Source: Roche Media News - August 29, 2023 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA)
Evrysdi available to treat people of all ages with SMA in the European Union, including babies from birth1Approval is based on interim data from ongoing RAINBOWFISH trial showing majority ofEvrysdi-treated babies were able to stand and walk within timeframes typical of healthy babies by 12 months ’ treatment2,3Evrysdi is the only non-invasive SMA therapy and is approved in 100 countries with more than 11,000 patients treated globallyBasel, 29 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved the extension of the Evrysdi ® (risdiplam) European Union (EU) marketing ...
Source: Roche Investor Update - August 29, 2023 Category: Pharmaceuticals Source Type: news

Vaccine Equality Is as Vital for Livestock as for People
PREVENT project in Tanzania/Iringa, 2021, Helena Kindole. Credit: Colin Dames/CEVABy Enrique Hernández PandoEl Castellar, Spain, Aug 22 2023 (IPS) El Castellar – For 33-year-old mother-of-seven and poultry farmer Helena Kindole in Chanya village in Tanzania, one of the main barriers to growing her chicken business is a lack of access to health services. But not for herself or her family – for her animals. With smallholder poultry farming often a lifeline for millions of low-income and rural families – accounting for 80% of poultry production in the region – access to medicines and vaccines is just as importan...
Source: IPS Inter Press Service - Health - August 22, 2023 Category: International Medicine & Public Health Authors: Enrique Hernandez Pando Tags: Africa Development & Aid Economy & Trade Food and Agriculture Health Inequality Sustainability TerraViva United Nations IPS UN Bureau Source Type: news

Urgent warning issued as new study links vaping to bronchitis and other serious conditions
Around three million people in the UK are thought to vape - putting them at risk of serious lung problems. (Source: Daily Express - Health)
Source: Daily Express - Health - August 17, 2023 Category: Consumer Health News Source Type: news

Young people are at risk of harsh respiratory problems after 30 days of e-cigarette use, study says
Young people are at risk of experiencing significant respiratory symptoms, including bronchitis and shortness of breath, after just 30 days of electronic cigarette use, according to a new study released Tuesday. Researchers from the Center for Tobacco Research at The Ohio State University…#puffbarelfbar #breezesmoke #alaynatackett (Source: Reuters: Health)
Source: Reuters: Health - August 15, 2023 Category: Consumer Health News Source Type: news

1-Hour Lung Protection Protocol Stops Viruses Cold
The simple act of breathing constantly exposes your lungs to all kinds of viruses, bacteria, particles of pollution, and other harmful foreign matter. And that means this overlooked organ has evolved its own special immune system to protect itself. Studies show that, like the rest of your body, your lungs operate two interactive protective systems — an adaptive and an innate immune system. The innate immune system in your lungs is made up of armies of T cells, B cells, and NK cells, like leukocytes, phagocytes, and macrophages. These cells, which are released by the alveoli and airway epithelial cells, identify foreign i...
Source: Al Sears, MD Natural Remedies - August 14, 2023 Category: Complementary Medicine Authors: Jacob Tags: Health Natural Cures Source Type: news

CHMP recommends Roche ’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA)
Positive recommendation is based on interim data from ongoing RAINBOWFISH trial which showed majority ofEvrysdi-treated babies were able to stand and walk within timeframes typical of healthy babies by 12 months ’ treatment1,2If approved by the European Commission,Evrysdi will be available to treat people of all ages with SMA in the European Union, including babies from birthEvrysdi is now approved in 100 countries with more than 8,500 patients treated globallyBasel, 21 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive o...
Source: Roche Media News - July 21, 2023 Category: Pharmaceuticals Source Type: news

CHMP recommends Roche ’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA)
Positive recommendation is based on interim data from ongoing RAINBOWFISH trial which showed majority ofEvrysdi-treated babies were able to stand and walk within timeframes typical of healthy babies by 12 months ’ treatment1,2If approved by the European Commission,Evrysdi will be available to treat people of all ages with SMA in the European Union, including babies from birthEvrysdi is now approved in 100 countries with more than 8,500 patients treated globallyBasel, 21 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive o...
Source: Roche Investor Update - July 21, 2023 Category: Pharmaceuticals Source Type: news

Wood Smoke Continues to Make Women Sick in El Salvador
Cecilia Menjivar, a tortilla maker in San Salvador, the capital of El Salvador, takes a break from cooking corn in a pot that is one meter high and 50 centimeters in diameter, heated by a wood stove. Many women in urban and rural areas run these small businesses, aware of the damage to their health caused by the smoke, but the economic situation forces them to use firewood, which is much cheaper than liquefied gas. CREDIT: Edgardo Ayala / IPSBy Edgardo AyalaSAN LUIS LA HERRADURA, El Salvador , Jul 4 2023 (IPS) Using a few dry sticks as fuel, Margarita Ramos of El Salvador lit the fire in her wood stove and set about frying...
Source: IPS Inter Press Service - Health - July 4, 2023 Category: International Medicine & Public Health Authors: Edgardo Ayala Tags: Active Citizens Civil Society Climate Change Development & Aid Editors' Choice Energy Environment Featured Food and Agriculture Gender Headlines Health Latin America & the Caribbean Population Poverty & SDGs Regional Categori Source Type: news

Warnings over increased asthma in children linked to vaping
There has been an increase in the number of children presenting with asthma, wheeze and bronchitis-type conditions because of vaping, a committee of influential MPs has heard. In an evidence session last week, the Health and Social Care Committee was also told of children with asthma who are unable to use school toilets because they... Read moreThe post Warnings over increased asthma in children linked to vaping appeared first on Nursing in Practice. (Source: Nursing in Practice)
Source: Nursing in Practice - July 4, 2023 Category: Nursing Authors: Megan Ford Tags: Clinical Latest news Paediatrics Source Type: news

Pope briefly at hospital for tests two months after bronchitis, returns to Vatican
Pope Francis has made a quick trip to a hospital for tests and returned to the Vatican, two months after he was hospitalized with an acute case of bronchitis (Source: ABC News: Health)
Source: ABC News: Health - June 6, 2023 Category: Consumer Health News Tags: Health Source Type: news

Pope briefly at hospital for tests two months after bronchitis, returns to Vatican
Pope Francis has made a quick trip to a hospital for tests (Source: ABC News: Health)
Source: ABC News: Health - June 6, 2023 Category: Consumer Health News Tags: Health Source Type: news

TREMFYA ® (guselkumab) Provides Sustained Improvements Across All Minimal Disease Activity Domains for Adults Living with Active Psoriatic Arthritis in Phase 3b Trial
SPRING HOUSE, PENNSYLVANIA, May 31, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 3b COSMOS clinical trial showing that treatment with TREMFYA® (guselkumab) provided sustainable improvements in all minimal disease activity (MDA)a domains through week 48 in adults living with active psoriatic arthritis (PsA) who previously had an inadequate response to one to two tumor necrosis factor inhibitors (TNFi-IR).[1] In a separate post-hoc analysis of the Phase 3 DISCOVER-1 and DISCOVER-2b clinical trial findings, TREMFYA was shown to be associated with prompt and su...
Source: Johnson and Johnson - May 31, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news